Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/1992
04/13/1992CA2052686A1 Use of a retinoid
04/11/1992WO1992007072A1 Method of inhibiting transcription utilizing nuclear receptors
04/11/1992CA2093811A1 Method of inhibiting transcription utilizing nuclear receptors
04/08/1992EP0479524A1 Method to reduce intraocular pressure without causing miosis
04/08/1992EP0479518A1 Compositions for topical application
04/08/1992EP0479479A1 Imadazole angiotensin II antagonists incorporating acidic functional groups
04/06/1992WO1992005698A1 Regulation of immunoglobulin production by interleukin-9
04/02/1992WO1992004901A1 Uracil reductase inactivators
04/02/1992WO1992004893A1 Non-aqueous liquid oral suspensions
04/02/1992CA2390654A1 Uracil reductase inactivators
04/02/1992CA2052517A1 Imidazole angiotensin ii antagonists incorporating acidic functional groups
04/02/1992CA2052438A1 Method to reduce intraocular pressure without causing miosis
04/01/1992EP0477625A1 Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
04/01/1992EP0477624A1 Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
03/1992
03/31/1992CA1298201C Method and compositions for treating obesity, depression, drug abuse and narcolepsy
03/29/1992WO1992005783A1 Ibuprofen-antihistamine combinations
03/29/1992CA2092566A1 Ibuprofen-antihistamine combinations
03/27/1992CA2051261A1 Cardiopulmonary bypass and organ transplant using a potassium channel activator
03/25/1992EP0477050A2 LPS-producing bacteria, LPSs, and LPS-containing medicines and veterinary medicines
03/25/1992EP0476711A2 Use of 5-fluorouracil for the treatment of AIDS
03/24/1992US5098910 Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs
03/24/1992US5098909 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
03/24/1992US5098889 Cognition activators, angiotensin converting enzyme inhibitors
03/19/1992WO1992004052A1 Modified antibodies with controlled clearance time
03/19/1992WO1992004027A1 Pharmaceutical compositions for use in treating aids
03/19/1992WO1992004022A1 Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders
03/19/1992WO1992004008A1 Composition for treating ocular pain
03/19/1992CA2073003A1 Composition for treating ocular pain
03/18/1992EP0216786B1 Purification, production and use of tumor necrosis factors
03/18/1992CA2050043A1 Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
03/18/1992CA2050042A1 Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
03/18/1992CA2049506A1 Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
03/17/1992US5096908 Method of inhibiting gastric acid secretion
03/17/1992US5096892 Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
03/17/1992US5096712 Administering tyrosine and synergistic indirect-acting sympathomimetic drug
03/17/1992CA1297407C Pharmaceutical which can be administered nasally, a process for it preparation, and its use
03/12/1992WO1992004021A1 Method for providing improved analgesic effect
03/11/1992WO1992004040A1 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
03/11/1992EP0473673A1 Method for protection from azt side effects and toxicity
03/11/1992EP0422097A4 Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo
03/10/1992US5095027 Antiischemic
03/10/1992CA1297024C Drug compositions stabilized against oxidation
03/10/1992CA1297023C Stabilized drug composition containing ascorbic acid
03/10/1992CA1297006C Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
03/05/1992WO1992004015A2 REGULATION OF T-CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR
03/05/1992WO1992004014A2 REGULATION OF NEOPLASTIC CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR
03/05/1992WO1992003165A1 New use of a monoclonal antibody
03/05/1992WO1992003151A1 Uses of recombinant colony stimulating factor-1
03/05/1992WO1992003137A1 Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
03/05/1992CA2090689A1 Regulation of t-cell proliferation via a novel 5htla receptor
03/05/1992CA2090688A1 Regulation of neoplastic cell proliferation via a novel 5htla receptor
03/04/1992EP0473442A1 A substituted pyrazine and its salts, compositions containing them and their use in medicine
03/04/1992EP0472639A1 Accumulation of drugs into liposomes by a proton gradient
03/04/1992EP0198893B1 Hair growth modification
03/04/1992EP0180597B1 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
03/03/1992US5093475 Hindered linking agents derived from 2-iminothiolanes and methods
03/03/1992US5093129 Method for treating addiction to a drug of abuse employing an ace inhibitor
03/03/1992US5093115 Method of preparing activated killer monocytes for treating colorectal cancer
03/03/1992CA1296633C Controlled release bases for pharmaceuticals
03/03/1992CA1296630C Dual phase solvent carrier system
03/01/1992CA2050264A1 Substituted pyrazine and its salts, compositions containing them and their use in medicine
02/1992
02/26/1992EP0472467A2 LPS-Containing analgesics and veterinary analgesics
02/26/1992EP0471787A1 A plasmid dna construct including the gene encoding a mammalian beta-nerve growth factor
02/25/1992US5091193 Zinc oxide, phytic acid and an ester of a fatty alcohol as anti-enzyme
02/25/1992US5091171 Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
02/21/1992CA2049533A1 Lps-containing analgesics and veterinary analgesics
02/20/1992WO1992002229A1 Immunosuppressive compositions
02/20/1992CA2088492A1 Immunosuppressive compositions
02/19/1992EP0471084A1 Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
02/18/1992US5089508 Administering a phenylacetamidinopiperidine-2,6-dione
02/18/1992US5089479 Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
02/18/1992CA1295998C Nucleosides and their use as antineoplastic agents
02/18/1992CA1295944C Pharmaceutical composition with antiviral or antitumor activity
02/13/1992DE4025499A1 Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen Use of antibodies BR55-2, derivatives thereof, and fragments conjugate on HIV infections
02/12/1992EP0470667A1 Composition containing a 4-quinolone derivative complexed with a divalent metal ion
02/12/1992EP0470117A1 Drugs (calcitonin gene-related peptides) for treating erectile dysfunctions.
02/11/1992US5087616 Linked by biodegradable polymer to epidermal growth factor
02/11/1992US5087560 Monoclonal antibody for use in drug resistant cancers and production thereof
02/11/1992US5087451 Treatment of periodontal disease
02/05/1992EP0191772B1 Acid-cleavable compound
02/04/1992US5086072 Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
02/04/1992US5086061 Use of beta blockers for the treatment of the progression of infantile axial myopia
02/03/1992WO1992002253A1 INTERLEUKIN-4 AND INTERLEUKIN-1β SYNERGISTICALLY INDUCE VCAM-1
01/1992
01/29/1992EP0468929A2 Stabilized pharmaceutical compositions
01/29/1992EP0468555A1 Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
01/29/1992EP0467957A1 Mercapto-acylamino acids
01/29/1992EP0467932A1 Urokinase-type plasminogen activator receptor
01/29/1992CN1058214A 1,3-oxathiolane nucleoside analogues
01/28/1992WO1992002240A2 Novel methods and compositions for treatment of angiogenic diseases
01/28/1992US5084274 Inhibition of arterial thrombotic occlusion or thromboembolism
01/28/1992US5084267 Sustained release compositions for treating periodontal disease
01/28/1992CA2082804A1 Methods and compositions for treatment of angiogenic diseases
01/25/1992WO1992001469A1 A composition providing improved clearance of bioactive substances from the bloodstream
01/25/1992CA2087971A1 Composition providing improved clearance of bioactive substances from the bloodstream
01/23/1992WO1992000994A1 Growth-promoting agent
01/23/1992WO1992000760A1 Method of treating neurological dysfunction using neurotransmitter enhances
01/22/1992EP0467710A2 Method for treating Parkinson's disease employing the ATP-sensitive potassium channel blocker quinine
01/22/1992EP0467709A2 Use of an ATP-sensitive potassium channel blocker to treat neuronal insult
01/22/1992EP0467365A2 Use of a 5-hydroxytryptamine-3(5-HT3) receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence
01/22/1992EP0466813A1 Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins